消灭Helicobacter pylori:一种前性比较随机试验,用于标准与优化四重疗法
Salma Souissi1, Cyrine Makni1, Basma Chaieb1
1University of Tunis El Manar, Departement of Gastroenterology, Mahmoud Matri Hospital, Ariana, 2080, Tunisia.
Future science OA
|May 31, 2024
概括
标准或剂量优化的阿莫西西林四倍疗法显示了类似的Helicobacter pylori根除率. 两种疗法都没有达到100%的有效性,这表明在治疗H. pylori感染方面存在持续的挑战.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 微生物学 微生物学
背景情况:
- * 治疗Helicobacter pylori感染存在重大挑战.
- *目前的根除方案缺乏100%的疗效.
- *阿莫西西林四倍疗法是一种常见的治疗方法.
研究的目的:
- * 为了比较标准和剂量优化的阿莫西西林四倍疗法之间的H. pylori根除率.
- * 评估优化治疗与标准四重疗法的有效性.
主要方法:
- * 88名未接受过治疗的H. pylori感染患者的前性比较研究.
- *随机分配到标准四倍疗法 (Qs-14) 或优化四倍疗法 (Qo-14).
- * 通过尿素呼吸试验确认了消灭.
主要成果:
- *在Qo-14 (84%ITT,82.1%PP) 和Qs-14 (70.4%ITT,77.7%PP) 之间的根除率没有显著差异.
- * ITT和PP的P值分别为0.127和0.473.
- * 在两组中观察到类似的遵守和耐受性.
结论:
- *与标准治疗相比,阿莫西西林四倍治疗的剂量优化并没有显著改善H. pylori根除率.
- *需要进一步的研究来提高H. pylori根除效率.
- * 标准和优化的四重疗法在原始患者中显示了可比的结果.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
363
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
363
Peptic Ulcer Disease IV: Management
87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
376
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
376
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
425
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
425
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
110
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
110
Gastritis III: Clinical Manifestations and Management
216
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
216


